Table 2.
Summary of Published Immune Profiling Studies Published by the BCCH group for B cells, NK cell and plasma marker populations associated with cGvHD in Separate Adult and Pediatric Cohorts.
| Cell population | Pediatric (0–18 years; N = 241)2Day 100 in cGvHD | Adult (≥ 18 years;N = 107)1Onset of cGvHD | |
|---|---|---|---|
| B cell populations | |||
| T1 - Immature/Transitional B cell population consistent with Breg cells | CD24hiCD38hiCD19+ | NS | Decreased4 |
| CD21 low B cells | CD21lo/CD19+ | Decreased | Increased |
| T2 transitional | CD38intCD10int of CD19+ | Decreased | NS |
| T3 transitional | CD38dimCD10lo of CD19+ | Decreased | NS |
| Mature Naïve | CD27- IgD+CD19+ | Decreased | Decreased |
|
Unswitched memory/
Marginal-zone like |
%CD27+IgD+ of CD19+ | Increased | Decreased |
| Classical switched memory | %CD27+IgD- of CD19+ | NS | Increased |
| NK cell populations | |||
| Regulatory CD56bright NK cells | Decreased Before onset – day 100 Decreased at onset |
NA Decreased at Onset1 Decreased in Donor cell infusion3 |
|
| Plasma markers | |||
| Day 100 | Onset of cGvHD | ||
| Aminopeptidase N (sCD13) | Increased | Increased but variable | |
| ST2 | Increased | Increased | |
| CXCL10 | NS | Increased | |
| CXCL9 | NS | Increased but variable | |
| ICAM-1 | Increased but variable | Increased but variable | |
1Rozmus (19) for adult data – N = 104; 44 with cGvHD onset (median of 207 days post-HCT; range 83–424 days) and 63 patients without cGvHD with sample collection a median of 194 days post-HCT (range 153–430 days); 2 Schultz KR (8) for pediatric data - N = 241 patients evaluated at day 100. 3Adult data on donor product infused as part of the CBMTG0601 trial (N = 79) (3). 4 To be defined as increased or decreased, the marker had to meet our definition of being a biologically relevant marker which included all of the following 3 criteria a) p value ≤0.05; b) ROC AUC ≥0.60; and effect ratio of ≥1.3 or ≤0.75.